Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.

An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.

The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.